Analysis of 10-year survival rate and its influencing factors among urban patients with lung cancer in Liaoning Province
YU Li-ya1, GUO Wei1, LYU Yi2, WANG Li-juan3, AN Xiao-xia4, MU Hui-juan1, PAN Guo-wei5, LI Yan-xia1
1. Liaoning Provincial Center for Disease Control and Prevention, Shenyang, Liaoning 110005, China; 2. Shenyang Municipal Center for Disease Control and Prevention, Shenyang, Liaoning 110031, China; 3. Anshan Municipal Center for Disease Control and Prevention, Anshan, Liaoning 114000, China; 4. Benxi Municipal Center for Disease Control and Prevention, Benxi, Liaoning 117000, China; 5. China Medical University, Shenyang, Liaoning 110122, China
Abstract：Objective To analyze the 10-year survival rate and its influencing factors among urban patients with lung cancer in Liaoning Province, and to provide a reference basis for formulating lung cancer prevention and treatment strategy. Methods A total of 483 lung cancer patients from Shenyang, Anshan and Benxi were selected by stratified random sampling from cancer incidence report database of Liaoning Province in 2000. General information, clinical information and survival status of the patients were retrospectively investigated by active and passive follow-up. The overall survival rate (OSR) and median survival time (T50) were calculated by life table method. The expected survival rate (ESR) and relative survival rate (RSR) were calculated by Ederer II method, and factors influencing the survival were analyzed by Cox regression model. Results The 10-year survival rates of the lung cancer patients from different characteristic cities in Liaoning Province were compared. The 10-year OSR, RSR and T50 of patients diagnosed with stage II, III and IV lung cancer were all lower than those of patients diagnosed with stage I lung cancer (all P<0.05). The 10-year T50 of lung cancer patients aged ≥ 65 years was lower than that of lung cancer patients aged < 65 years (χ2=10.043, P=0.002), and the 10-year T50 of non-operative lung cancer patients was lower than that of operative lung cancer patients (χ2=35.715, P<0.001). Multivariate Cox regression analysis showed that the relative mortality risk of the urban patients with lung cancer increased by 0.015 times (HR=1.015, 95%CI=1.004-1.026) for every one-year increase in age. The relative risks of death of patients with stage II, III and IV lung cancer were 2.794 (HR=2.794, 95%CI=1.710-4.564), 2.286 (HR=2.286, 95%CI=1.599-3.270) and 3.995 (HR=3.995, 95%CI=2.855-5.590) times that of patients with stage I lung cancer. Conclusion The 10-year survival rate of the lung cancer patients in Liaoning Province in 2000 was significantly lower than that in developed countries. The low rates of early diagnosis and treatment may be the main cause.
于丽娅, 郭薇, 吕艺, 王丽娟, 安晓霞, 穆慧娟, 潘国伟, 礼彦侠. 辽宁省城市肺癌患者10年生存率及其影响因素分析[J]. 实用预防医学, 2021, 28(12): 1432-1436.
YU Li-ya, GUO Wei, LYU Yi, WANG Li-juan, AN Xiao-xia, MU Hui-juan, PAN Guo-wei, LI Yan-xia. Analysis of 10-year survival rate and its influencing factors among urban patients with lung cancer in Liaoning Province. , 2021, 28(12): 1432-1436.
[1] Sato T,Watanabe A,Kondo H,et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases[J]. J Thorac Cardiovasc Surg,2015,149(1):64-71. [2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clinicians,2018,68(6):394-424. [3] 国家癌症中心.2017中国肿瘤登记年报[M]. 北京:人民卫生出版社,2018:1-25. [4] 陈万青, 张思维, 邹小农, 等. 2004—2005年中国肺癌死亡情况分析[J]. 中华预防医学杂志, 2010,44(5): 378-382. [5] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health,2018,6:e555-e567. [6] 李其龙,马新源,姚开颜,等. 1987—2002年嘉善县肺癌生存率分析[J]. 中国肿瘤,2008,17(7):565-566. [7] 华召来,郭国平,周琴,等.扬中市主要恶性肿瘤发病率及生存率分析[J]. 中国肿瘤,2008,17(7):565-566. [8] 陈建国,朱健,沈康,等.启东1972—2011年肺癌生存率分析[C]. 第八届中国肿瘤学术大会暨第十三届海峡两岸肿瘤学术会议,济南,2014. [9] 董景五. 疾病和有关健康问题的国际统计分类[M]:第3版. 北京: 人民卫生出版社, 2008:1-25. [10] Corazziari I, Quinn M,Capocaccia R. Standard cancer patient population for age standardising survival ratios[J].Eur J Cancer,2004,40(15):2307-2316. [11] 李科,林国桢,李燕,等.广州市2009年报告发病的鼻咽癌患者生存率及其影响因素分析[J]. 实用预防医学,2016,23(12):1412-1414. [12] Ito Y, Miyashiro I, Ito H, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data[J].Cancer Sci,2014,105:1480-1486. [13] Lee JY,JungK-W,Park S,et al. Long-term survival of cancer patients in Korea, 1993-2007: national cancer registry study[J].Asian Pac J Cancer Prev,2011,11(6):1459-1464. [14] Jansen L, Castro FA, Gondos A, et al.Recent cancer survival in Germany: an analysis of common and less common cancers[J].IJC,2015,136(11):2649-2658. [15] Vazquez M,Carter D,Brambilla E,et al. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications[J]. Lung Cancer, 2009, 64(2): 148-154. [16] Seder CW,Kubasiak JC,Pithadia R,et al. Angiogenesis biomarkers may be useful in the management of patients with indeterminate pulmonary nodules[J]. Ann Thorac Surg, 2015, 100(2):429-436. [17] 杜冬明,刘晓红,杨延平,等.2014—2018年浙江省丽水市肺癌发病和死亡趋势分析[J].实用预防医学,2021,28(2):212-215. [18] 杨志,林春龙. 肺癌治疗的现状与进展[J].临床医学进展,2018, 8(9):837-843.
2021, Vol. 28 
